<DOC>
	<DOC>NCT00388960</DOC>
	<brief_summary>The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung cancer.</brief_summary>
	<brief_title>Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically/cytologically proven small cell lung cancer Extensive disease Measurable disease World Health Organization (WHO) performance status 02 Age 18 years or older Normal baseline cardiac function No prior systemic chemotherapy for small cell lung cancer Adequate organ function including bone marrow, kidney, and liver No history of interstitial lung disease or pulmonary fibrosis No history of prior malignancy unless patient has been disease free for greater than 5 years, or the tumour was a nonmelanoma skin cancer or insitu carcinoma of the cervix No pregnancy or breast feeding; patients of childbearing potential must agree to use an appropriate method of contraception Written informed consent before randomization Exclusion criteria: Preexisting peripheral neuropathy (greater than Grade 1, CTCAE version 3.0) Uncontrolled or severe cardiovascular disease Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>amrubicin</keyword>
</DOC>